Does Estradiolnorethindrone Acetate Transdermal System Interact with Nevirapine?
CDI records a moderate classification for Estradiolnorethindrone Acetate Transdermal System and Nevirapine. The stored summary is: CYP3A4 inducer that may reduce plasma concentrations of estrogens, possibly decreasing therapeutic effects and altering uterine bleeding profile. The mechanism involves cyp3a4 induction. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Moderate
- Estradiolnorethindrone Acetate Transdermal System Class
- Estrogen
- Nevirapine Class
- Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
CYP3A4 induction
What To Tell Your Doctor or Pharmacist
If you are taking Estradiolnorethindrone Acetate Transdermal System and your doctor is considering prescribing Nevirapine (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider